What is Remeron (Mirtazapine)?
Remeron (mirtazapine) is a tetracyclic antidepressant classified as a noradrenergic and specific serotonergic antidepressant (NaSSA) that is FDA-approved for the treatment of major depressive disorder. 1
Mechanism of Action
Mirtazapine works through a unique mechanism distinct from other antidepressants. It antagonizes presynaptic α2-adrenergic autoreceptors and heteroreceptors, which enhances both noradrenergic and serotonergic neurotransmission 1. Additionally, it blocks postsynaptic serotonin 5-HT2 and 5-HT3 receptors while leaving 5-HT1A receptors unaffected, resulting in specific increased serotonergic activity at these receptors 2, 3. The drug also acts as an antagonist at histamine H1 receptors, peripheral α1-adrenergic receptors, and has minimal muscarinic receptor activity 1.
Clinical Indications
FDA-Approved Use
- Major Depressive Disorder: Mirtazapine is approved for treating major depression, with demonstrated efficacy equivalent to tricyclic antidepressants and SSRIs 4, 5
Off-Label Uses (Based on Guidelines)
Multiple clinical guidelines recognize mirtazapine for off-label applications:
- Insomnia: Listed as a sedating low-dose antidepressant option when accompanied by comorbid depression or after other treatment failures, though evidence for efficacy when used alone is relatively weak 6
- Depression in Alzheimer's Disease: Recommended at 7.5-30 mg at bedtime; noted as "potent and well tolerated" with benefits for promoting sleep, appetite, and weight gain 7
- Depression in Older Adults: Identified as a preferred agent alongside citalopram, escitalopram, sertraline, venlafaxine, and bupropion 8
- Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Starting dose 15 mg once daily, titrated to maximum 45 mg daily; associated with sleep disorders, constipation or diarrhea, anxiety, increased appetite and weight gain 9
Dosing and Administration
Standard dosing for depression: 15-45 mg once daily at bedtime 1. The recommended starting dose is 15 mg daily, which can be increased according to response 8. Peak plasma concentrations occur within approximately 2 hours, with a half-life of 20-40 hours enabling once-daily dosing 1, 2.
Special populations:
- Elderly patients: Start at lower doses (7.5 mg at bedtime) due to increased risk of confusion, over-sedation, and hyponatremia 7, 1
- Hepatic or renal impairment: Dosage decrease may be necessary as clearance is reduced in moderate to severe impairment 1
Adverse Effects Profile
Common side effects include 1, 2:
- Drowsiness and sedation (most prominent)
- Increased appetite and weight gain (occurs more frequently than with other antidepressants)
- Dry mouth
- Constipation
Advantages over other antidepressants: Mirtazapine has minimal anticholinergic effects compared to tricyclics, lacks significant cardiovascular effects, and essentially lacks serotonergic side effects such as gastrointestinal symptoms, insomnia, and sexual dysfunction 2, 8.
Serious but rare effects: Agranulocytosis and neutropenia have been reported, though these are uncommon 3. QT prolongation and Torsades de Pointes have been reported in overdose situations 1.
Clinical Advantages
Rapid onset of action: Evidence suggests mirtazapine may have a faster onset than SSRIs, with improvements in sleep disturbances and anxiety symptoms potentially occurring within the first week 2, 4. Studies showed superiority over fluoxetine at weeks 3-4 and over paroxetine and citalopram at weeks 1-2 5.
Beneficial side effect profile for specific patients: The sedating properties and appetite stimulation make mirtazapine particularly useful for patients with depression accompanied by insomnia, anxiety, or poor appetite 7, 10, 2.
Drug Interactions and Safety
Mirtazapine has low potential for drug interactions via cytochrome P450 2D6, making it suitable for patients requiring polytherapy 5. However, caution is advised when combining with other CNS depressants, alcohol, or serotonergic medications 1.
Contraindications and cautions:
- Not recommended during pregnancy or nursing 6
- Use caution in patients with compromised respiratory function, hepatic impairment, or heart failure 6
- REMERONSolTab contains phenylalanine and should be avoided in patients with phenylketonuria 1
Formulations
Available as: